Document is current

Article History

First Online: 23 April 2015

Competing interests

: Y.A. has/had consultancy relationships and/or has received research funding in the area of systemic sclerosis and related conditions from Actelion, Bayer, Biogen, Bristol–Meyers Squibb, Inventiva, Medac, Pfizer, Roche/Genentech, Sanofi-Aventis and Servier. R.S. has/had consultancy relationships and/or has received research funding in the area of systemic sclerosis and related conditions from Actelion, Gilead, Hoffman–La Roche, Intermune, MedImmune, Novartis, Regeneron and United Therapeutics. O.D. has/had consultancy relationships and/or has received research funding in the area of systemic sclerosis and related conditions from 4D Science, Actelion, Active Biotec, Bayer, Biogen, Biovitrium, Bristol–Meyers Squibb, Boehringer, EpiPharm, Ergonex, GlaxoSmithKline, Inventiva, Medac, Novartis, Pfizer, Pharmacyclics, Roche/Genentech, Sanofi-Aventis, Serodapharm, Sinoxa and United BioSource. J.P. has/had consultancy relationships and/or has received research funding in the area of systemic sclerosis and related conditions from Actelion, Bayer, Biogen, and Roche/Genentech. C.P.D. has/had consultancy relationships and/or has received research funding in the area of systemic sclerosis and related conditions from Actelion, Biogen, Biovitrum, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Inventiva, Novartis, Pfizer, Roche/Genetech and Sanofi-Aventis. J.V. has acted as a consultant or received research funding from Biogen/Idec, Takeda, the US National Institutes of Health, US Department of Defense. M.T. declares no competing interests.